Kazia Therapeutics
KZIA
5 hedge funds and large institutions have $365K invested in Kazia Therapeutics in 2019 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
25% more capital invested
Capital invested by funds: $293K → $365K (+$72K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
17% less funds holding
Funds holding: 6 → 5 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$5.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$25K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$8.06K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $210K | +$5.6K | +34 | +3% |
|
2
Renaissance Technologies
New York
| $115K | – | – | – |
|
|
TW
3
Transform Wealth
Greenwood Village,
Colorado
| $35K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $5K | -$8.06K | -49 | -61% |
|
|
RE
5
RBC Europe
London,
United Kingdom
| $107 | – | – | – |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$25K | -220 | Closed |
|
KZIA Hedge Fund Activity: Q1 2019 in Review
5 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q1 2019, worth a combined $365K — up 25% from $293K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of KZIA and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $5.6K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $25K sold.
- 5 institutional investors held Kazia Therapeutics (KZIA) as of Q1 2019, down from 6 in Q4 2018.
- Funds reported $365K of Kazia Therapeutics stock for Q1 2019, up 25% quarter-over-quarter.
- 0 funds opened new Kazia Therapeutics positions in Q1 2019 and 1 closed out, a net change of -1 holder.
- The largest Kazia Therapeutics buyer in Q1 2019 was Morgan Stanley, an estimated $5.6K added.
- The largest Kazia Therapeutics seller in Q1 2019 was Susquehanna International Group, an estimated $25K sold.
Based on aggregated 13F filings for Q1 2019.